Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25148139 | 1.00 | KMT2A (0.43) | KMT2ATPSAB1EPHX2TLR2PTPN1 | |
| SCHEMBL84334 | 0.93 | FURIN (0.40) | KMT2ATPSAB1TLR2PTPN1 | |
| SCHEMBL13196227 | 0.92 | TLR2 (0.45) | KMT2ATPSAB1TLR2PTPN1SIRT2 | |
| SCHEMBL29371674 | 0.92 | TLR2 (0.45) | KMT2ATPSAB1TLR2PTPN1SIRT2 | |
| SCHEMBL13311052 | 0.92 | TLR2 (0.45) | KMT2ATPSAB1TLR2PTPN1SIRT2 | |
| SCHEMBL29694582 | 0.91 | FURIN (0.39) | KMT2ATPSAB1TLR2PTPN1 | |
| SCHEMBL31681559 | 0.87 | MDM2 (0.43) | TPSAB1TLR2PTPN1SIRT2SIRT1 | |
| SCHEMBL23477323 | 0.87 | TLR2 (0.45) | KMT2ATLR2PTPN1SIRT2SIRT1 | |
| SCHEMBL13044093 | 0.86 | CASP3 (0.45) | TLR2PTPN1SIRT2SIRT1 | |
| SCHEMBL13830419 | 0.86 | CASP3 (0.45) | TLR2PTPN1SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276074-A1 | BRM AND BRG1 TARGETING ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | PRELUDE THERAPEUTICS INCORPORATED | 2025-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276074-A1 | BRM AND BRG1 TARGETING ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | CRBN, RBX1, SMARCE1 | KMT2A 253/4885TPSAB1 4498/4885EPHX2 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.